Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Autologous TIL 1383I TCR transduced T-cells |
Synonyms | |
Therapy Description |
Autologous TIL 13831 TCR transduced T cells are patient-derived peripheral blood mononuclear cells engineered to express a T-cell receptor (TCR) targeting melanoma-specific tyrosinase, potentially resulting in increased immune response against tyrosinase-expressing tumors (Journal for ImmunoTherapy of Cancer 2013;1:P31; NCI Drug Dictionary). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Autologous TIL 1383I TCR transduced T-cells | TIL 1383I T Cell Receptor-Transduced Autologous T cells | Autologous TIL 1383I TCR transduced T-cells are patient-derived peripheral blood mononuclear cells engineered to express a T-cell receptor (TCR) targeting melanoma-specific tyrosinase, which potentially induce an increased immune response against tyrosinase-expressing tumors (Journal for ImmunoTherapy of Cancer 2013;1:P31; NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT02870244 | Phase I | Autologous TIL 1383I TCR transduced T-cells | Adoptive T Cell Immunotherapy for Advanced Melanoma Using Engineered Lymphocytes | Recruiting | USA | 0 |